110 related articles for article (PubMed ID: 9432042)
21. IgM paraproteinaemia: disease associations and laboratory features.
Roberts-Thomson PJ; Nikoloutsopoulos T; Smith AJ
Pathology; 2002 Aug; 34(4):356-61. PubMed ID: 12190295
[TBL] [Abstract][Full Text] [Related]
22. [Monoclonal gammopathy of undetermined significance and asymptomatic multiple myelom in the year 2014 ].
Adam Z; Krejčí M; Pour L; Sevčíková E; Křivanová A; Rehák Z; Koukalová R; Cermáková Z; Vaníček J; Sevčíková S
Vnitr Lek; 2014 Oct; 60(10):861-79. PubMed ID: 25382009
[TBL] [Abstract][Full Text] [Related]
23. Immunophenotypic characterization of plasma cells from monoclonal gammopathy of undetermined significance patients. Implications for the differential diagnosis between MGUS and multiple myeloma.
Ocqueteau M; Orfao A; Almeida J; Bladé J; González M; García-Sanz R; López-Berges C; Moro MJ; Hernández J; Escribano L; Caballero D; Rozman M; San Miguel JF
Am J Pathol; 1998 Jun; 152(6):1655-65. PubMed ID: 9626070
[TBL] [Abstract][Full Text] [Related]
24. Epidemiology of Monoclonal Gammopathy of Undetermined Significance (MGUS): The experience from the specialized registry of hematologic malignancies of Basse-Normandie (France).
Cabrera Q; Macro M; Hebert B; Cornet E; Collignon A; Troussard X
Cancer Epidemiol; 2014 Aug; 38(4):354-6. PubMed ID: 24880205
[TBL] [Abstract][Full Text] [Related]
25. Prognostic significance of paraproteinaemia in rheumatoid arthritis.
Kelly C; Baird G; Foster H; Hosker H; Griffiths I
Ann Rheum Dis; 1991 May; 50(5):290-4. PubMed ID: 2042982
[TBL] [Abstract][Full Text] [Related]
26. [Incidence Analysis of Monoclonal Gammopathy of Undetermined Significance in People over 40 Years of Age].
Zhang R; Wang L; Zhang ZH; Pang NN; Zhao JL; Qu JH
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2019 Apr; 27(2):623-628. PubMed ID: 30998181
[TBL] [Abstract][Full Text] [Related]
27. [Malignant transformation of monoclonal gammopathy of undetermined significance].
Decaux O; Avet-Loiseau H; Grosbois B
Presse Med; 2007 Dec; 36(12 Pt 3):1985-96. PubMed ID: 17509811
[TBL] [Abstract][Full Text] [Related]
28. [Study of monoclonal gammopathy in Kagawa Prefectural Central Hospital].
Uchida M; Taida N; Kanao M; Kagamihara H; Kuwajima M
Rinsho Byori; 2004 Jul; 52(7):574-9. PubMed ID: 15344556
[TBL] [Abstract][Full Text] [Related]
29. Are neurological complications of monoclonal gammopathy of undetermined significance underestimated?
Steiner N; Schwärzler A; Göbel G; Löscher W; Wanschitz J; Gunsilius E
Oncotarget; 2017 Jan; 8(3):5081-5091. PubMed ID: 27974705
[TBL] [Abstract][Full Text] [Related]
30. [Rapid development of primary amyloidosis after two years' follow-up of monoclonal gammopathy of undetermined significance (MGUS)].
Kanoh T; Inoue M; Okuma M
Rinsho Ketsueki; 1993 Aug; 34(8):952-6. PubMed ID: 8411650
[TBL] [Abstract][Full Text] [Related]
31. Prognostic validation of the international classification of immunoglobulin M gammopathies: a survival advantage for patients with immunoglobulin M monoclonal gammopathy of undetermined significance?
Gobbi PG; Baldini L; Broglia C; Goldaniga M; Comelli M; Morel P; Morra E; Cortelazzo S; Bettini R; Merlini G
Clin Cancer Res; 2005 Mar; 11(5):1786-90. PubMed ID: 15756000
[TBL] [Abstract][Full Text] [Related]
32. Long-term follow-up of patients with monoclonal gammopathy of undetermined significance after kidney transplantation.
Naina HV; Harris S; Dispenzieri A; Cosio FG; Habermann TM; Stegall MD; Dean PG; Prieto M; Kyle RA; Rajkumar SV; Leung N
Am J Nephrol; 2012; 35(4):365-71. PubMed ID: 22473253
[TBL] [Abstract][Full Text] [Related]
33. Characterization of monoclonal gammopathy in patients with amyotrophic lateral sclerosis.
Wolf HH; Posa A; Panitz S; Kornhuber M; Hanisch F
Acta Neurol Scand; 2015 Sep; 132(3):212-5. PubMed ID: 25644365
[TBL] [Abstract][Full Text] [Related]
34. [Acquired peripheral neuropathies associated with monoclonal gammopathy].
Gajos A; Kieliś W; Szadkowska I; Chmielowska E; Niewodniczy A; Bogucki A
Neurol Neurochir Pol; 2007; 41(2):169-75. PubMed ID: 17530580
[TBL] [Abstract][Full Text] [Related]
35. The impact of M-component type and immunoglobulin concentration on the risk of malignant transformation in patients with monoclonal gammopathy of undetermined significance.
Gregersen H; Mellemkjaer L; Ibsen JS; Dahlerup JF; Thomassen L; Sørensen HT
Haematologica; 2001 Nov; 86(11):1172-9. PubMed ID: 11694403
[TBL] [Abstract][Full Text] [Related]
36. [Incidence, clinico-biological characteristics, and clinical course of 1,203 monoclonal gammopathies (1971-1992)].
Giraldo P; Rubio-Félix D; Cortés T; Delgado P; Franco E; Gimeno J; Tapia M; Giralt M
Sangre (Barc); 1994 Oct; 39(5):343-50. PubMed ID: 7754438
[TBL] [Abstract][Full Text] [Related]
37. The value of the bone marrow plasma cell cytoplasmic light chain ratio in differentiating between multiple myeloma and monoclonal gammopathy of undetermined significance.
Majumdar G; Grace RJ; Singh AK; Slater NG
Leuk Lymphoma; 1992 Dec; 8(6):491-3. PubMed ID: 1297481
[TBL] [Abstract][Full Text] [Related]
38. Fracture risk in monoclonal gammopathy of undetermined significance.
Melton LJ; Rajkumar SV; Khosla S; Achenbach SJ; Oberg AL; Kyle RA
J Bone Miner Res; 2004 Jan; 19(1):25-30. PubMed ID: 14753733
[TBL] [Abstract][Full Text] [Related]
39. [Pitfalls of monoclonal gammopathy].
Meuleman N
Rev Med Brux; 2013 Sep; 34(4):335-8. PubMed ID: 24195249
[TBL] [Abstract][Full Text] [Related]
40. Differentiation of monoclonal gammopathy of undetermined significance and multiple myeloma using flow cytometric characteristics of plasma cells.
Sezer O; Heider U; Zavrski I; Possinger K
Haematologica; 2001 Aug; 86(8):837-43. PubMed ID: 11522540
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
